Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Depreciation & Amortization (CF) (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $1.9 million in Q2 2025.

  • For Q2 2025, Depreciation & Amortization (CF) fell 4.97% year-over-year to $1.9 million; the TTM value through May 2025 reached $8.0 million, up 0.92%, while the annual FY2025 figure was $8.0 million, 0.92% up from the prior year.
  • Depreciation & Amortization (CF) reached $1.9 million in Q2 2025 per LFCR's latest filing, down from $2.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $5.9 million in Q4 2021 and bottomed at $1.8 million in Q4 2023.
  • Average Depreciation & Amortization (CF) over 5 years is $3.2 million, with a median of $2.9 million recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): increased 24.77% in 2021, then crashed 50.21% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $5.9 million in 2021, then tumbled by 50.12% to $2.9 million in 2022, then crashed by 39.93% to $1.8 million in 2023, then grew by 15.74% to $2.0 million in 2024, then fell by 6.36% to $1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $1.9 million in Q2 2025, $2.1 million in Q1 2025, and $2.0 million in Q4 2024.